Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer


Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced a late-breaking abstract presentation on 18F-rhPSMA-7.3 at the upcoming 2022 AUA Annual Meeting (AUA2022), to be held May 13 to 16 in New Orleans, La. 18F-rhPSMA-7.3 is an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid (rh) PET imaging agent. The SPOTLIGHT study (NCT04186845) is a Phase 3, multi-center, single-arm imaging study, conducted in the United States and Europe, to evaluate the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy. Details of the presentation are listed below.

Highlighted Oral Presentation

Friday, May 13, 2022 Morning Plenary Session

Presentation:

Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: results from the prospective, Phase 3, multicenter SPOTLIGHT study

Abstract Number:

Late-Breaking Abstract PLLBA-02

Presenter:

Mark T. Fleming, MD, Virginia Oncology Associates, U.S. Oncology Research, Norfolk, Va., on behalf of the SPOTLIGHT Study Group

Session Title & Times:

Plenary Session 7:30 AM ? 11:30 AM CT

Oral Presentation:

11:13 ? 11:21 AM CT

Location:

New Orleans Ernest N. Morial Convention Center, Great Hall A

Blue Earth Diagnostics invites participants at AUA2022 to attend the presentation above and to learn more about the Company at Booth 455. For full session details and scientific presentation listings, please see the AUA online program here.

About Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)

rhPSMA compounds consist of a radiohybrid ("rh") Prostate-Specific Membrane Antigen-targeted receptor ligand which attaches to and is internalized by prostate cancer cells and they may be radiolabeled with 18F for PET imaging, or with isotopes such as 177Lu or 225Ac for therapeutic use ? creating a true theranostic technology. They may play an important role in patient management in the future, and offer the potential for precision medicine for men with prostate cancer. Radiohybrid technology and rhPSMA originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018, and therapeutic rights in 2020, and has sublicensed the therapeutic application to its sister company Blue Earth Therapeutics. Blue Earth Diagnostics has completed two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: ("SPOTLIGHT," NCT04186845), in men with recurrent disease and ("LIGHTHOUSE," NCT04186819), in men with newly diagnosed prostate cancer. Currently, rhPSMA compounds are investigational and have not received regulatory approval.

About Blue Earth Diagnostics

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company's success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics' expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.

About Bracco Imaging

Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: www.braccoimaging.com.


These press releases may also interest you

at 12:51
Team Queso, a leading esports club in mobile...

at 12:49
Vast Therapeutics announces promising results with a nitric oxide releasing drug candidate under investigation for infections caused by Mycobacterium abscessus, a multi-drug resistant bacteria for which there are currently no FDA-approved treatments....

at 12:34
Empowering young people from diverse backgrounds across the globe is central to addressing global challenges like climate change. AFS Intercultural Programs, a global non-profit educational exchange organization, is proud to launch a new scholarship...

at 12:30
Emergent Software has been named one of the Top 200 Workplaces in Minnesota by the Star Tribune. A complete list of those selected is available at StarTribune.com/topworkplaces2022 and will also be published in the Star Tribune Top Workplaces special...

at 12:25
"We are excited to be acknowledged as a Google Premier Partner. What an incredible accomplishment for our 15th anniversary," says Brendon Schenecker, Founder of SB. "We strive for exceptional service and exceptional results...

at 12:15
The "Radar System Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global radar system market reached a value of US$ 32.3 Billion in 2021. Looking...



News published on 5 may 2022 at 08:35 and distributed by: